title: Dose-related increase in liver heme catabolism during rabbit aflatoxicosis.
abstract: Aflatoxin B1 (AFB1) has been reported to decrease microsomal hepatic cytochrome P450 (P450) content and increase both total plasma bilirubin concentration and liver heme oxygenase activity. The purposes of this study were to determine whether liver hemoproteins contents and heme catabolizing enzymes were affected by the mycotoxin and whether these alterations were linked to hyperbilirubinemia. Male New Zealand rabbits were divided into three groups of five animals, each receiving for 5 days either arabic gum as vehicle or AFB1 at a daily oral dose of 0.05 or 0.10 mg/kg. These treatments affected neither cytochrome b5 content nor NADPH-cytochrome reductase activity. A linear dose-dependent decrease in cytochrome P450 content and increases in both heme oxygenase and biliverdin reductase activities were observed. Bilirubin UDP-glucuronyltransferase activity was dramatically decreased at both doses, whereas cholestasis occurred only at 0.10 mg/kg. An exponential dose-dependent increase in plasma bilirubin concentration was also observed. Both the simultaneous exponential increase in bilirubinemia associated to a reduced bilirubin UDP-glucuronyltransferase activity and the absence of cholestasis at 0.05 mg/kg, suggested that the hyperbilirubinemia is more probably related to an increased heme catabolism than to an altered bile duct permeability.
authors.affiliation: Département des Sciences Biologiques et Fonctionnelles, Pharmacie-Toxicologie, E.N.V.T., Toulouse, France.
authors.forename: P
authors.initials: P
authors.lastname: Guerre
authors.forename: V
authors.initials: V
authors.lastname: Burgat
authors.forename: P
authors.initials: P
authors.lastname: Galtier
mesh_terms: D000284:Administration, Oral; D016604:Aflatoxin B1 / Q000008:administration & dosage*; D000818:Animals; D001663:Bilirubin / Q000097:blood; D002273:Carcinogens / Q000008:administration & dosage*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D014453:Glucuronosyltransferase / Q000378:metabolism; D006418:Heme / Q000378:metabolism*; D006419:Heme Oxygenase (Decyclizing) / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D015651:Mycotoxicosis / Q000378:metabolism*; D010088:Oxidoreductases / Q000378:metabolism; D044925:Oxidoreductases Acting on CH-CH Group Donors; D011817:Rabbits
chemical_list: D002273:Carcinogens; C019787:bilirubin glucuronoside glucuronosyltransferase; D006418:Heme; D003577:Cytochrome P-450 Enzyme System; D016604:Aflatoxin B1; D010088:Oxidoreductases; D006419:Heme Oxygenase (Decyclizing); D044925:Oxidoreductases Acting on CH-CH Group Donors; C019789:biliverdin reductase; D014453:Glucuronosyltransferase; D001663:Bilirubin